In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Making accessibility strategy part of your rare disease trial planning
In this article, Laura Iliescu, director of patient advocacy strategy at ICON Plc, discusses strategies to improve inclusion of people with disabilities in rare disease trials.
-
How decentralised and hybrid clinical trials can support subject recruitment and retention to support clinical trial success
Read Laney Preheim's article in International Pharmaceutical Industry.
-
Diverse teams drive great performance
Steve Cutler participated in the Business & Finance CEO Q&A in which he outlined his ambitions and priorities for ICON.
-
Transforming clinical trials in a rapidly shifting landscape
Dr Ute Berger, President, Development & Commercialisation Solutions outlines how ICON is transforming clinical trials in a rapidly shifting landscape in the Executive Interview in Drug Development & Delivery.
Copyright Drug Development & Delivery.
-
Data doesn't cut it - Payer engagement requires a humanistic approach
A drug’s ability to reach the market is essential; however, pharma manufacturers have struggled to meet the increased pressure to demonstrate the value of their drugs, particularly in therapeutic areas over-populated with treatment options. Data surrounding the success and efficacy of a drug are rarely sufficient to convince stakeholders that the drug is worth the investment. Payers have displayed a need for a more humanistic approach, and against this backdrop, manufacturers need to reconsider their engagement strategies.
-
Developing mRNA vaccine technology
In this article, Dinah Knotts, Vice President of Project Management at ICON, speaks about mRNA vaccine technology and what further opportunities it can offer in fighting infectious diseases.
-
Decentralised clinical trials and sites: friend or foe?
Emily Mitchell, Executive Director, Decentralised Clinical Trials, contributes to this piece in Clinical Trials Arena on the role of sites in a DCT setting.
-
Due diligence and beyond
Dr. Sandra Eagle outlines how due diligence has evolved from a discrete standalone technical assessment, to now being an integrated part of the holistic development continuum of an asset.
-
LEO Pharma enters clinical trial partnership with ICON
This news article, published on PM Live, highlights how the partnership will advance trial execution within medical dermatology.
-
The contribution of companies during the Covid-19 pandemic
Rose Kidd, President, Operations Delivery outlines the role ICON played in the search for vaccines and treatments for Covid-19 in the American Chamber of Commerce Ireland 2023 US-Ireland Business Report.
2023 American Chamber of Commerce Ireland
